{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:08Z","timestamp":1740107708278,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006738","name":"Medicinska Fakulteten, Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005390","name":"Alfred \u00d6sterlunds Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate the association between chronic inflammatory rheumatic diseases (CIRD) and drug use disorder (DUD). Individuals aged\u2009\u2265\u200930\u00a0years in 2009 that met the following conditions were included: residing in the Sk\u00e5ne region, Sweden, with at least one healthcare contact in person and no history of DUD (ICD-10 codes F11-F16, F18-F19) during 1998\u20132009 (<jats:italic>N<\/jats:italic>\u2009=\u2009649,891). CIRD was defined as the presence of rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or systemic lupus erythematosus. Treating CIRD as a time-varying exposure, we followed people from January 1, 2010 until a diagnosis of DUD, death, relocation outside the region, or December 31, 2019, whichever occurred first. We used flexible parametric survival models adjusted for attained age, sociodemographic characteristics, and coexisting conditions for data analysis. There were 64 (95% CI 62\u201366) and 104 (88\u2013123) incident DUD per 100,000 person-years among those without and with CIRD, respectively. CIRD was associated with an increased risk of DUD in age-adjusted analysis (hazard ratio [HR] 1.77, 95% CI 1.49\u20132.09). Almost identical HR (1.71, 95% CI 1.45\u20132.03) was estimated after adjustment for sociodemographic characteristics, and it slightly attenuated when coexisting conditions were additionally accounted for (1.47, 95% CI 1.24\u20131.74). Fully adjusted HRs were 1.49 (1.21\u20131.85) for RA, 2.00 (1.38\u20132.90) for AS, and 1.58 (1.16\u20132.16) for PsA. More stringent definitions of CIRD didn\u2019t alter our findings. CIRD was associated with an increased risk of DUD independent of sociodemographic factors and coexisting conditions.<jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>A register-based cohort study including 649,891 individuals aged\u226530 residing in the Sk\u00e5ne region, Sweden, was conducted<\/jats:italic>.\u2022 <jats:italic>Chronic inflammatory rheumatic diseases were associated with higher risks of drug use disorder independent of sociodemographic factors and coexisting conditions<\/jats:italic>.<\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>","DOI":"10.1007\/s10067-023-06755-w","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:02:37Z","timestamp":1693209757000},"page":"81-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory rheumatic diseases and the risk of drug use disorders: a register-based cohort study in Sweden"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4254-9099","authenticated-orcid":false,"given":"Ali","family":"Kiadaliri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Dell\u2019Isola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Englund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"6755_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3899\/jrheum.110901","volume":"88","author":"P Jacobs","year":"2011","unstructured":"Jacobs P, Bissonnette R, Guenther LC (2011) Socioeconomic burden of immune-mediated inflammatory diseases\u2013focusing on work productivity and disability. J Rheumatol Suppl 88:55\u201361. https:\/\/doi.org\/10.3899\/jrheum.110901","journal-title":"J Rheumatol Suppl"},{"key":"6755_CR2","unstructured":"Bergman MJ (2006) Social and economic impact of inflammatory arthritis. Postgrad Med 119:5\u201311"},{"key":"6755_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/BOR.0000000000000868","volume":"34","author":"C Anastasiou","year":"2022","unstructured":"Anastasiou C, Yazdany J (2022) Review of publications evaluating opioid use in patients with inflammatory rheumatic disease. Curr Opin Rheumatol 34:95\u2013102. https:\/\/doi.org\/10.1097\/BOR.0000000000000868","journal-title":"Curr Opin Rheumatol"},{"key":"6755_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11926-022-01065-7","volume":"24","author":"WB Nowell","year":"2022","unstructured":"Nowell WB, Gavigan K, Silver SL (2022) Cannabis for rheumatic disease pain: a review of current literature. Curr Rheumatol Rep 24:119\u2013131. https:\/\/doi.org\/10.1007\/s11926-022-01065-7","journal-title":"Curr Rheumatol Rep"},{"key":"6755_CR5","doi-asserted-by":"publisher","unstructured":"Mallery Lankford C, Paez K, Yang M et al (2022) Adapting the Current Opioid Misuse Measure (COMM) for people with chronic pain and disability due to arthritis: the development of the COMM 11-PWDA. Disabil Health J 15:101296. https:\/\/doi.org\/10.1016\/j.dhjo.2022.101296","DOI":"10.1016\/j.dhjo.2022.101296"},{"key":"6755_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/acr2.11339","volume":"3","author":"K Kowalec","year":"2021","unstructured":"Kowalec K, Carney H, Patel M et al (2021) Prevalence and risk factors of substance use disorder in rheumatoid arthritis. ACR Open Rheumatol 3:889\u2013896. https:\/\/doi.org\/10.1002\/acr2.11339","journal-title":"ACR Open Rheumatol"},{"key":"6755_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3899\/jrheum.191370","volume":"48","author":"JA Singh","year":"2021","unstructured":"Singh JA, Cleveland JD (2021) Time trends in opioid use disorder hospitalizations in gout, rheumatoid arthritis, fibromyalgia, osteoarthritis, and low back pain. J Rheumatol 48:775\u2013784. https:\/\/doi.org\/10.3899\/jrheum.191370","journal-title":"J Rheumatol"},{"key":"6755_CR8","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1007\/s10067-021-05715-6","volume":"40","author":"JA Singh","year":"2021","unstructured":"Singh JA (2021) Time-trends in cocaine, hallucinogen, amphetamine, and sedative\/anxiolytic\/hypnotic use disorder hospitalizations in rheumatic diseases: a national time-trends study. Clin Rheumatol 40:3007\u20133014. https:\/\/doi.org\/10.1007\/s10067-021-05715-6","journal-title":"Clin Rheumatol"},{"key":"6755_CR9","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1093\/rheumatology\/keab112","volume":"60","author":"JA Singh","year":"2021","unstructured":"Singh JA (2021) Comment on: Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis. Rheumatology (Oxford) 60:e222\u2013e224. https:\/\/doi.org\/10.1093\/rheumatology\/keab112","journal-title":"Rheumatology (Oxford)"},{"key":"6755_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/1536867x0900900206","volume":"9","author":"PC Lambert","year":"2009","unstructured":"Lambert PC, Royston P (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265\u2013290. https:\/\/doi.org\/10.1177\/1536867x0900900206","journal-title":"Stata Journal"},{"key":"6755_CR11","unstructured":"Royston P, Lambert PC (2011) Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model. Stata Press, College Station, TX, USA"},{"key":"6755_CR12","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130\u20131139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83","journal-title":"Med Care"},{"key":"6755_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.psc.2018.07.009","volume":"41","author":"R Shah","year":"2018","unstructured":"Shah R, Zanarini MC (2018) Comorbidity of borderline personality disorder: current status and future directions. Psychiatr Clin North Am 41:583\u2013593. https:\/\/doi.org\/10.1016\/j.psc.2018.07.009","journal-title":"Psychiatr Clin North Am"},{"key":"6755_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jpain.2007.08.002","volume":"9","author":"LA McWilliams","year":"2008","unstructured":"McWilliams LA, Clara IP, Murphy PD et al (2008) Associations between arthritis and a broad range of psychiatric disorders: findings from a nationally representative sample. J Pain 9:37\u201344. https:\/\/doi.org\/10.1016\/j.jpain.2007.08.002","journal-title":"J Pain"},{"key":"6755_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.drugalcdep.2018.08.013","volume":"192","author":"LT Wu","year":"2018","unstructured":"Wu LT, Zhu H, Ghitza UE (2018) Multicomorbidity of chronic diseases and substance use disorders and their association with hospitalization: Results from electronic health records data. Drug Alcohol Depend 192:316\u2013323. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.013","journal-title":"Drug Alcohol Depend"},{"key":"6755_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1471-2474-7-37","volume":"7","author":"SB Patten","year":"2006","unstructured":"Patten SB, Williams JV, Wang J (2006) Mental disorders in a population sample with musculoskeletal disorders. BMC Musculoskelet Disord 7:37. https:\/\/doi.org\/10.1186\/1471-2474-7-37","journal-title":"BMC Musculoskelet Disord"},{"key":"6755_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/01.psy.0000195821.25811.b4","volume":"68","author":"PE Stang","year":"2006","unstructured":"Stang PE, Brandenburg NA, Lane MC et al (2006) Mental and physical comorbid conditions and days in role among persons with arthritis. Psychosom Med 68:152\u2013158. https:\/\/doi.org\/10.1097\/01.psy.0000195821.25811.b4","journal-title":"Psychosom Med"},{"key":"6755_CR18","doi-asserted-by":"publisher","unstructured":"Luther AWM, Reaume SV, Qadeer RA et al (2020) Substance use disorders among youth with chronic physical illness. Addict Behav 110:106517. https:\/\/doi.org\/10.1016\/j.addbeh.2020.106517","DOI":"10.1016\/j.addbeh.2020.106517"},{"key":"6755_CR19","doi-asserted-by":"publisher","unstructured":"Sanchez-Roige S, Kember RL, Agrawal A (2022) Substance use and common contributors to morbidity: a genetics perspective. EBioMedicine 83:104212. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104212","DOI":"10.1016\/j.ebiom.2022.104212"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06755-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06755-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06755-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:09:05Z","timestamp":1704690545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06755-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6755"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06755-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2023,8,28]]},"assertion":[{"value":"29 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval from the Lund University Ethical Review Committee (Dnr 2011\u2013432 and 2014\u2013276) and performed in accordance with the Declaration of Helsinki. We used anonymised information from national and regional registers and the need for individual informed consent was waived by the Lund University Ethical Review Committee. Information about the project was advertised in the major newspapers where a possibility to opt-out was offered. This is a principle used in Sweden for population-wide studies using non-identifiable register data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AK acts as a part-time (7.5% FTE) scientific advisor for Arthro Therapeutics providing digital treatment for musculoskeletal pain. ME declares consultancy for Cellcolabs AB and Key2Compliance AB. AD declares no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}